CN105939717B - 治疗和预防同种抗体驱动的慢性移植物抗宿主病的方法 - Google Patents

治疗和预防同种抗体驱动的慢性移植物抗宿主病的方法 Download PDF

Info

Publication number
CN105939717B
CN105939717B CN201480074674.4A CN201480074674A CN105939717B CN 105939717 B CN105939717 B CN 105939717B CN 201480074674 A CN201480074674 A CN 201480074674A CN 105939717 B CN105939717 B CN 105939717B
Authority
CN
China
Prior art keywords
certain embodiments
cgvhd
substituted
inhibitor
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480074674.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105939717A (zh
Inventor
布鲁斯·R·布拉泽尔
赖安·弗林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacyclics LLC
University of Minnesota System
Original Assignee
Pharmacyclics LLC
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics LLC, University of Minnesota System filed Critical Pharmacyclics LLC
Priority to CN201910760757.3A priority Critical patent/CN110478353B/zh
Publication of CN105939717A publication Critical patent/CN105939717A/zh
Application granted granted Critical
Publication of CN105939717B publication Critical patent/CN105939717B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
CN201480074674.4A 2013-12-02 2014-12-02 治疗和预防同种抗体驱动的慢性移植物抗宿主病的方法 Active CN105939717B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910760757.3A CN110478353B (zh) 2013-12-02 2014-12-02 治疗和预防同种抗体驱动的慢性移植物抗宿主病的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361910944P 2013-12-02 2013-12-02
US61/910,944 2013-12-02
US201461973178P 2014-03-31 2014-03-31
US61/973,178 2014-03-31
PCT/US2014/068177 WO2015084857A1 (en) 2013-12-02 2014-12-02 Methods of treating and preventing alloantibody driven chronic graft versus host disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910760757.3A Division CN110478353B (zh) 2013-12-02 2014-12-02 治疗和预防同种抗体驱动的慢性移植物抗宿主病的方法

Publications (2)

Publication Number Publication Date
CN105939717A CN105939717A (zh) 2016-09-14
CN105939717B true CN105939717B (zh) 2019-09-13

Family

ID=53270044

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910760757.3A Active CN110478353B (zh) 2013-12-02 2014-12-02 治疗和预防同种抗体驱动的慢性移植物抗宿主病的方法
CN201480074674.4A Active CN105939717B (zh) 2013-12-02 2014-12-02 治疗和预防同种抗体驱动的慢性移植物抗宿主病的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910760757.3A Active CN110478353B (zh) 2013-12-02 2014-12-02 治疗和预防同种抗体驱动的慢性移植物抗宿主病的方法

Country Status (14)

Country Link
US (6) US20150157634A1 (enExample)
EP (1) EP3076975A4 (enExample)
JP (5) JP2017501140A (enExample)
KR (2) KR20160085817A (enExample)
CN (2) CN110478353B (enExample)
AU (4) AU2014360758B2 (enExample)
BR (1) BR112016012158A2 (enExample)
CA (2) CA3210338A1 (enExample)
EA (1) EA201691020A1 (enExample)
IL (4) IL315228A (enExample)
MX (2) MX389020B (enExample)
PH (2) PH12020552048A1 (enExample)
TW (3) TWI743019B (enExample)
WO (1) WO2015084857A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3218491A1 (en) 2012-06-04 2013-12-12 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
MX392373B (es) 2013-10-25 2025-03-24 Pharmacyclics Llc Uso de ibrutinib en el tratamiento de enfermedad injerto contra huesped cronica
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
ES2863700T3 (es) 2016-03-22 2021-10-11 Mayo Found Medical Education & Res Uso de inhibidores de ácido graso sintasa para tratar la fibrosis
WO2018002958A1 (en) * 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
US20200054721A1 (en) * 2016-10-21 2020-02-20 Bruce R. Blazar Materials and methods for treating or preventing graft-versus-host-disease
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
US12496303B2 (en) 2020-10-19 2025-12-16 Washington University Conditioning agents for use in allogeneic hematopoietic stem cell transplantation
US20240025990A1 (en) * 2020-12-01 2024-01-25 City Of Hope Prevention and treatment of graft-versus-host disease (gvhd)
US20240139195A1 (en) * 2021-01-30 2024-05-02 Beigene Switzerland Gmbh Methods of treating chronic active antibody-mediated rejection using btk inhibitors
US20240287781A1 (en) 2023-02-28 2024-08-29 Toto Ltd. Wall-mounted flush toilet

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102887900A (zh) * 2006-09-22 2013-01-23 药品循环公司 布鲁顿酪氨酸激酶的抑制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US20060182723A1 (en) * 2005-01-25 2006-08-17 Spellberg Brad J Methods for treating refractory infections in neutropenic individuals
CN101421269A (zh) * 2006-01-13 2009-04-29 环状药物公司 酪氨酸激酶抑制剂及其用途
AU2009270856B2 (en) * 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
EP2424368B1 (en) * 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
IN2012DN02764A (enExample) * 2009-08-31 2015-09-18 Amplimmune Inc
EA201890869A3 (ru) * 2010-06-03 2019-03-29 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk)
US20120071497A1 (en) * 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
ES2548414T3 (es) * 2011-07-08 2015-10-16 Novartis Ag Novedosos derivados de pirrolo pirimidina
US9522917B2 (en) * 2012-04-11 2016-12-20 Acerta Pharma B.V. Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
WO2013177596A2 (en) * 2012-05-25 2013-11-28 Sloan Kettering Institute For Cancer Methods for treating gi syndrome and graft versus host disease
WO2014127200A1 (en) * 2013-02-15 2014-08-21 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
MX392373B (es) * 2013-10-25 2025-03-24 Pharmacyclics Llc Uso de ibrutinib en el tratamiento de enfermedad injerto contra huesped cronica
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102887900A (zh) * 2006-09-22 2013-01-23 药品循环公司 布鲁顿酪氨酸激酶的抑制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Bruton’s tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity";Fatih M Uckun 等;《Expert Opin. Ther. Patents》;20101231;第20卷(第11期);第1461页左栏倒数1-2行-右栏1-29行 *

Also Published As

Publication number Publication date
CN105939717A (zh) 2016-09-14
MX2016006955A (es) 2016-09-07
CN110478353B (zh) 2022-12-30
JP2023029899A (ja) 2023-03-07
AU2020204276A1 (en) 2020-07-16
IL292522A (en) 2022-06-01
IL276683A (en) 2020-09-30
KR20230104754A (ko) 2023-07-10
AU2024278490A1 (en) 2025-01-09
TW202402295A (zh) 2024-01-16
IL245715A0 (en) 2016-07-31
JP2020105181A (ja) 2020-07-09
CN110478353A (zh) 2019-11-22
IL315228A (en) 2024-10-01
MX389020B (es) 2025-03-20
CA2932255C (en) 2023-10-10
BR112016012158A2 (pt) 2017-09-26
KR20230104754A9 (ko) 2024-11-15
EP3076975A4 (en) 2017-05-03
AU2022203810B2 (en) 2024-10-03
WO2015084857A1 (en) 2015-06-11
US20210177854A1 (en) 2021-06-17
CA2932255A1 (en) 2015-06-11
MX2022000209A (es) 2022-02-03
PH12016501051A1 (en) 2016-08-15
AU2014360758A1 (en) 2016-06-16
TW201605454A (zh) 2016-02-16
TW202228700A (zh) 2022-08-01
AU2014360758B2 (en) 2020-03-26
US20250381188A1 (en) 2025-12-18
US20180078558A1 (en) 2018-03-22
JP2025118595A (ja) 2025-08-13
KR20160085817A (ko) 2016-07-18
TWI743019B (zh) 2021-10-21
JP2017501140A (ja) 2017-01-12
EA201691020A1 (ru) 2017-01-30
PH12020552048A1 (en) 2022-05-11
AU2022203810A1 (en) 2022-06-23
CA3210338A1 (en) 2015-06-11
US20150157634A1 (en) 2015-06-11
US20230100137A1 (en) 2023-03-30
US20240293409A1 (en) 2024-09-05
JP2024072291A (ja) 2024-05-27
EP3076975A1 (en) 2016-10-12

Similar Documents

Publication Publication Date Title
CN105939717B (zh) 治疗和预防同种抗体驱动的慢性移植物抗宿主病的方法
KR102357526B1 (ko) 이식편 대 숙주 질환의 치료 및 예방 방법
US20240293557A1 (en) Proteolysis targeting chimeras and methods of use thereof
US12233047B2 (en) Pharmaceutical combination and use thereof
US20250017878A1 (en) Use of nadolol to treat chronic obstructive pulmonary disease by blockage of the arrestin-2 pathway
US20220002287A1 (en) Indazole kinase inhibitor and use thereof
JP2017531684A (ja) 腎障害の治療のための１，２−ベンゾチアゾール化合物
AU2024234602A1 (en) USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2
HK40031991A (en) Methods of treating and preventing graft versus host disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: California, USA

Applicant after: PHARMACYCLICS LLC

Applicant after: REGENTS OF THE University OF MINNESOTA

Address before: California, USA

Applicant before: PHARMACYCLICS LLC

Applicant before: Regents of the University of Minnesota

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: Illinois, USA

Patentee after: PHARMACYCLICS LLC

Country or region after: U.S.A.

Patentee after: REGENTS OF THE University OF MINNESOTA

Address before: California, USA

Patentee before: PHARMACYCLICS LLC

Country or region before: U.S.A.

Patentee before: REGENTS OF THE University OF MINNESOTA

CP03 Change of name, title or address